Intech Investment Management LLC Sells 39,331 Shares of Edwards Lifesciences Corporation $EW

Intech Investment Management LLC lowered its stake in Edwards Lifesciences Corporation (NYSE:EW) by 50.9% in the second quarter, Holdings Channel.com reports. The institutional investor owned 37,913 shares of the medical research company’s stock after selling 39,331 shares during the quarter. Intech Investment Management LLC’s holdings in Edwards Lifesciences were worth $2,965,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of EW. Quantbot Technologies LP acquired a new position in Edwards Lifesciences during the 1st quarter worth $26,000. SouthState Corp bought a new position in shares of Edwards Lifesciences in the first quarter worth about $27,000. Rosenberg Matthew Hamilton acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $28,000. Costello Asset Management INC bought a new stake in Edwards Lifesciences during the 1st quarter valued at approximately $29,000. Finally, NewSquare Capital LLC grew its holdings in Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. This trade represents a 24.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 2.2%

Shares of NYSE EW opened at $85.85 on Thursday. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.21. The company has a 50-day moving average of $78.52 and a two-hundred day moving average of $77.93. The company has a market cap of $49.82 billion, a PE ratio of 12.35, a P/E/G ratio of 3.97 and a beta of 1.03. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EW. Evercore ISI increased their price objective on Edwards Lifesciences from $88.00 to $92.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. National Bankshares set a $92.00 price objective on Edwards Lifesciences in a research report on Friday, October 31st. Wells Fargo & Company lifted their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research report on Thursday, August 7th. Truist Financial increased their price target on shares of Edwards Lifesciences from $87.00 to $90.00 and gave the stock a “hold” rating in a research report on Monday, November 3rd. Finally, Stifel Nicolaus upped their price objective on Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.